Registration is open for 4th SOHO Israel Annual Meeting
SOHO Israel is pleased to announce that the 4th Annual SOHO Israel Meeting, held in conjunction with the 10th International Davidoff Conference, will
Ambassador Program
News
Society Updates
Lymphoma Roundtable
Lymphoma
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
CELMoDs in the second-line setting in follicular lymphoma
In this video, the group discusses golcadomide's potential in relapsed or refractory follicular lymphoma, including combinations with rituximab in heavily pretreated patients, ongoing
Multiple Myeloma
News
FDA approves daratumumab, hyaluronidase-fihj, VRd in newly diagnosed myeloma
The US Food and Drug Administration (FDA) granted approval for daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) to be used in combination
Myeloproliferative Neoplasms
Primary Myelofibrosis
News
FDA grants zavabresib orphan drug designation in myelofibrosis
The US Food and Drug Administration (FDA) has granted orphan drug designation to zavabresib (OPN-2853) for the treatment of myelofibrosis. The generic name
SOHO Asia 2026
Ambassador Program
News
Society Updates
1st SOHO Asia hopes to empower hematology community across Asia
Dr. Hsin-An Hou, a professor at National Taiwan University Hospital, shares his excitement about the regional impact of the inaugural SOHO Asia meeting,
Leukemia
Acute Lymphoblastic Leukemia
FDA grants breakthrough designation to CAR-T therapy sofi-cel
Sofi-cel, an allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy, has previously received regenerative medicine advanced therapy, fast track, orphan drug, and rare pediatric disease
Multiple Myeloma
News
FDA clears IND for KLN-1010 in relapsed or refractory myeloma
The United States Food and Drug Administration cleared the Investigational New Drug application for KLN-1010, an in vivo BCMA-targeted CAR-T therapy, for patients
Lymphoma
Aggressive B-Cell Lymphomas
News
Malaysia regulatory agency approves supplemental NDA for selinexor in relapsed or refractory DLBCL
The Malaysian National Pharmaceutical Regulatory Agency approved selinexor (XPOVIO) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at
ASH 2025
Myelodysplastic Syndromes
Dr. Garcia-Manero presents phase 2 ASTX030 results in MDS and other blood cancers
In this video interview with SOHO Insider, Guillermo García-Manero, MD, professor and chief of the Section of Myelodysplastic Syndromes and ad interim chair
Lymphoma Roundtable
ASH 2025
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
Indolent B-Cell Lymphomas
Roundtable Discussions
Video Interviews
What are the therapeutic combinations in large cell lymphoma?
In this video, the group discusses adding novel agents to frontline chemotherapy in large B-cell lymphoma, including polatuzumab vedotin with R-CHOP and bispecific